- Home
- SWTX vs ATAT Comparison
SWTX vs ATAT Comparison
Compare SWTX & ATAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- ATAT
- Stock Information
- Founded
- SWTX 2017
- ATAT 2013
- Country
- SWTX United States
- ATAT China
- Employees
- SWTX N/A
- ATAT N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- ATAT Hotels/Resorts
- Sector
- SWTX Health Care
- ATAT Consumer Discretionary
- Exchange
- SWTX Nasdaq
- ATAT Nasdaq
- Market Cap
- SWTX 3.5B
- ATAT 3.3B
- IPO Year
- SWTX 2019
- ATAT 2022
- Fundamental
- Price
- SWTX $46.26
- ATAT $28.46
- Analyst Decision
- SWTX Buy
- ATAT Strong Buy
- Analyst Count
- SWTX 7
- ATAT 1
- Target Price
- SWTX $56.86
- ATAT $36.80
- AVG Volume (30 Days)
- SWTX 8.7M
- ATAT 1.6M
- Earning Date
- SWTX 05-20-2025
- ATAT 05-22-2025
- Dividend Yield
- SWTX N/A
- ATAT 1.57%
- EPS Growth
- SWTX N/A
- ATAT 71.91
- EPS
- SWTX N/A
- ATAT 1.26
- Revenue
- SWTX $191,589,000.00
- ATAT $992,989,819.00
- Revenue This Year
- SWTX $86.36
- ATAT $27.82
- Revenue Next Year
- SWTX $69.02
- ATAT $22.18
- P/E Ratio
- SWTX N/A
- ATAT $22.59
- Revenue Growth
- SWTX 3417.33
- ATAT 55.34
- 52 Week Low
- SWTX $28.21
- ATAT $15.22
- 52 Week High
- SWTX $62.00
- ATAT $33.32
- Technical
- Relative Strength Index (RSI)
- SWTX 58.93
- ATAT 66.81
- Support Level
- SWTX $46.10
- ATAT $24.29
- Resistance Level
- SWTX $46.27
- ATAT $25.48
- Average True Range (ATR)
- SWTX 0.90
- ATAT 1.05
- MACD
- SWTX 0.58
- ATAT 0.70
- Stochastic Oscillator
- SWTX 99.46
- ATAT 82.86
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.